Beyond the horizon: Emerging therapeutic approaches in Myelodysplastic Neoplasms

Management of Myelodysplastic Neoplasms (MDS) presents a complex challenge and should always be tailored to each patient's individual case, focusing on both quality of life and extension of lifespan. The International Prognostic Scoring System-Revised (IPSS-R) has been a cornerstone in the risk stratification and management of MDS. It provides a comprehensive framework for predicting survival and the risk of transformation to acute myeloid leukemia (AML), based on five key parameters: cytogenetics, bone marrow blast percentage, and levels of hemoglobin, platelets, and absolute neutrophil count1.
Source: Experimental Hematology - Category: Hematology Authors: Source Type: research